Dr. Maggie De Block:

The system in Netherlands is very different because here we have national insurance administration procedures. In the Netherlands it is very different and there are private organisations and the Zorgverzekeringswet. It has several organisations or insurance companies and they take the decision. It is not down to the administration in the country or the minister taking the decision. They negotiate between them and give the information to the minister about how much they are prepared to pay for the drug in question. It is very different here and we have a national administration, the RIZIV-INAMI, and it has private partners.